Noevir Holdings Co., Ltd. (4928)

Name: Noevir Holdings Co., Ltd. (4928) — storico dei bilanci
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Storico di ricavi, utili e flussi di cassa dai bilanci ufficiali.

Consumer Defensive · Wall Street (USA) · Ultimo aggiornamento: 2026-10-02

Noevir Holdings Co., Ltd. develops, produces, and sells cosmetics, toiletries, medical supplies, and food products in China, Taiwan, South Korea, Hong Kong, Singapore, Thailand, the United States, and Canada. The company's Cosmetics segment develops, produces, and sells skincare products under various brands, including Noevir and Nameraka Honpo; excel make up line products and NOV hypoallergenic cosmetics, as well as provides contract manufacturing services for cosmetics and quasi drugs.

Dati chiave

Capitalizzazione di mercato: JPY 152 billion
Ricavi (esercizio chiuso a 2025-09-30): JPY 64.7B
Utile netto: JPY 8.0B
Margine lordo: 66.9%
Margine netto: 12.4%

Vedi grafici interattivi e bilanci completi → Modello di valutazione (DCF) →

Conto economico annuale

Conto economico	2025-09-30	2024-09-30	2023-09-30	2022-09-30
Entrate totali	JPY 64.7B	JPY 63.8B	JPY 62.6B	JPY 61.1B
Utile lordo	JPY 43.3B	JPY 43.2B	JPY 42.6B	JPY 42.1B
Risultato Operativo (EBIT)	JPY 11.1B	JPY 11.4B	JPY 11.0B	JPY 10.1B
Reddito netto	JPY 8.0B	JPY 8.0B	JPY 7.7B	JPY 7.6B

Fonte: bilanci pubblici della società (SEC). Verificare su SEC EDGAR prima di fare affidamento su qualsiasi cifra.

Stati patrimoniali, flussi di cassa, dati trimestrali e indici completi nel visualizzatore interattivo di 4928. /companies/us/4928

Aziende simili

7956 · Pigeon Corporation

Le informazioni di questo sito sono solo a scopo educativo e informativo; non costituiscono consulenza finanziaria. Non vengono pubblicati prezzi obiettivo né raccomandazioni.

English version →Tutte le azioni

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.